Should You Invest in Biotech Stocks Now?

The Biotech Investment Landscape

In this podcast, Motley Fool analysts Tim Beyers and Karl Thiel delve into the evolving biotech investment landscape. They explore the increasing venture capital funding in biotechnology, the characteristics of a viable biotech company, and a comparison between two prominent players: Viking Therapeutics and Eli Lilly.

The rise in biotech funding from venture capitalists and wealthy individuals has been notable. Recent data from LACA shows that total VC funding in biotech increased year over year for the first time since 2021, reaching $21.4 billion in 2024 compared to $16.1 billion in 2023. This marks a significant increase and surpasses pre-pandemic levels. Moreover, 2024 recorded the strongest quarter since early 2022, indicating a positive trend.

Family offices have also shown increased interest in biotech investments, committing larger amounts to early-stage biotech companies. This shift reflects a growing confidence in the sector, as family offices often have longer investment horizons than traditional VCs.

Evaluating Biotech Opportunities

Biotech has historically been a hit-or-miss investment, with the Motley Fool Rule Breakers Scorecard highlighting this volatility. The XBI, a biotech-themed ETF, has underperformed the market, losing 35% and 60% in two instances. However, the current environment presents new opportunities due to increased private market activity and the emergence of more IPOs.

Karl Thiel emphasizes the need for guarded optimism, noting that while venture capital funding is stabilizing, there are still challenges such as high interest rates, lack of M&A activity, and regulatory concerns at the FDA. Despite these issues, there are signs of improvement, including multibillion-dollar M&A deals and a more favorable market outlook.

Thiel suggests that investors should focus on careful selection within the biotech sector rather than broad market exposure. He highlights the importance of evaluating a company's science, capital, and proximity to market approval. Late-stage companies with strong pipelines and near-term commercialization potential are particularly attractive.

Comparing Viking Therapeutics and Eli Lilly

When comparing Viking Therapeutics and Eli Lilly, Thiel notes that Eli Lilly offers safety and stability, with successful weight-loss drugs like Mounjaro and Zepbound. These products have surpassed competitors like Ozempic and show strong market performance. Additionally, Eli Lilly has a robust pipeline and diverse portfolio across various pharmaceutical areas.

On the other hand, Viking Therapeutics presents a more speculative opportunity. While it has promising late-stage drugs, it is not yet close to market. Thiel views Viking as a potential M&A candidate, given its strong data and the growing interest in obesity treatments. However, it carries higher risk due to its earlier stage of development.

Key Considerations for Investors

Investors should consider several factors when evaluating biotech companies. These include the quality of the science, the strength of the capital, and the company’s proximity to market approval. Companies with strong pipelines and near-term commercialization potential are more attractive. Additionally, the potential for M&A activity can enhance returns, especially for companies with innovative technologies or unique drug candidates.

The Future of Biotech

The biotech industry continues to evolve, with new developments and opportunities emerging regularly. As the sector matures, it is essential for investors to stay informed and make well-researched decisions. The combination of increased funding, regulatory progress, and strategic M&A activity suggests a positive outlook for biotech investments.

Historical Perspective

The history of biotechnology dates back to the 1970s, with companies like CDIS Corp (now known as Cepheid) playing a pivotal role. Founded in 1971, CDIS Corp was involved in developing PCR technology, which revolutionized genetic research. While Genentech is often credited as the first modern biotech company, CDIS Corp's contributions highlight the industry's rich history and ongoing innovation.

As the biotech sector continues to grow, investors must remain vigilant and adaptable. By focusing on strong fundamentals, innovative science, and strategic opportunities, investors can navigate the complexities of this dynamic industry and potentially achieve significant returns.